Quantcast
Connect with us

FDA chief Scott Gottlieb resigns

Published

on

U.S. Food and Drug Administration chief Scott Gottlieb said on Tuesday he plans to step down in a month, calling into question how the agency will handle critical issues such as e-cigarette use among teens and efforts to increase competition in prescription drugs.

The Department of Health and Human Services, which oversees the FDA, announced Gottlieb’s resignation on Tuesday.

ADVERTISEMENT

Gottlieb was well regarded and won bipartisan support for his efforts to curb the use of flavored e-cigarettes by youths, speed approval times for cheap generic medicines to increase competition and bring down prescription drug prices and boost the use of cheaper versions of expensive biotech medicines, called biosimilars.

“Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use,” Health and Human Services (HHS) Secretary Alex Azar said in a statement.

The FDA did not respond to a request for comment.

The Washington Post first reported on Tuesday that Gottlieb planned to resign.

ADVERTISEMENT

“Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!” Republican President Donald Trump wrote on Twitter on Tuesday.

In his resignation letter, Gottlieb touted several of the agency’s initiatives, including efforts to curb tobacco use, decrease the rate of opioid addiction, speed up approval of generic drugs and streamline the process for novel medical technologies such as gene therapy.

“I’m immensely grateful for the opportunity to help lead this wonderful agency, for the support of my colleagues, for the public health goals we advanced together, and the strong support of @SecAzar and @realDonaldTrump – This has been a wonderful journey and parting is very hard,” he wrote on Twitter, referring to Azar and Trump by their Twitter handles.

ADVERTISEMENT

CURBING E-CIGARETTE USE

Gottlieb’s signature policy initiative was his effort to reduce teen e-cigarette use. He expressed concern over the rise in the number of youths using flavored e-cigarettes after preliminary federal data showed teenage use had surged by more than 75 percent since last year, which the FDA described as an “epidemic.”

Under Gottlieb, the FDA issued a ban on the sale of fruit- and candy-flavored electronic cigarettes in convenience stores and gas stations, meaning only tobacco, mint and menthol flavors can be sold at these outlets.

ADVERTISEMENT

The FDA also introduced stricter age-verification requirements for online sales of e-cigarettes. The proposal is at the White House Office of Management and Budget for review.

Gottlieb is a conservative physician and former deputy FDA commissioner under Republican President George W. Bush. Before becoming head of the FDA, he was a longtime healthcare investor and consultant who sat on multiple company boards. He surprised critics who worried about his ties to the pharmaceutical industry by speaking out about rising drug prices and drug companies’ tactics to keep competitors off the market.

Gottlieb also sought to introduce the FDA into the drug pricing conversation, an unusual move for the agency, which typically oversees clinical trials and drug approvals. He often touted that the agency had approved more than 1,000 generic drugs as evidence that it was helping to curb prescription drug prices, a top priority of Trump’s administration.

ADVERTISEMENT

In January, Gottlieb said in a tweet that he did not plan to leave the agency after speculation that he planned to step down. “We’ve got a lot of important policy we’ll advance this year,” he wrote in the January tweet.

Following the report of Gottlieb’s resignation, the Nasdaq Biotechnology Index turned negative. It closed down 0.5 percent. Similarly, shares of Amgen Inc erased their gains and Gilead Sciences Inc shares added to losses. Amgen shares finished down 0.5 percent and Gilead shares closed 1.6 percent lower.

Reporting by Yasmeen Abutaleb and Tim Ahmann; editing by Eric Beech and Jonathan Oatis

ADVERTISEMENT

Enjoy this piece?

… then let us make a small request. Like you, we here at Raw Story believe in the power of progressive journalism — and we’re investing in investigative reporting as other publications give it the ax. Raw Story readers power David Cay Johnston’s DCReport, which we've expanded to keep watch in Washington. We’ve exposed billionaire tax evasion and uncovered White House efforts to poison our water. We’ve revealed financial scams that prey on veterans, and legal efforts to harm workers exploited by abusive bosses. We’ve launched a weekly podcast, “We’ve Got Issues,” focused on issues, not tweets. And unlike other news outlets, we’ve decided to make our original content free. But we need your support to do what we do.

Raw Story is independent. You won’t find mainstream media bias here. We’re not part of a conglomerate, or a project of venture capital bros. From unflinching coverage of racism, to revealing efforts to erode our rights, Raw Story will continue to expose hypocrisy and harm. Unhinged from billionaires and corporate overlords, we fight to ensure no one is forgotten.

We need your support to keep producing quality journalism and deepen our investigative reporting. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us in the future. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you. Click to donate by check.

Enjoy this piece?

… then let us make a small request. Like you, we here at Raw Story believe in the power of progressive journalism — and we’re investing in investigative reporting as other publications give it the ax. Raw Story readers power David Cay Johnston’s DCReport, which we've expanded to keep watch in Washington. We’ve exposed billionaire tax evasion and uncovered White House efforts to poison our water. We’ve revealed financial scams that prey on veterans, and efforts to harm workers exploited by abusive bosses. We’ve launched a weekly podcast, “We’ve Got Issues,” focused on issues, not tweets. Unlike other news sites, we’ve decided to make our original content free. But we need your support to do what we do.

Raw Story is independent. You won’t find mainstream media bias here. We’re not part of a conglomerate, or a project of venture capital bros. From unflinching coverage of racism, to revealing efforts to erode our rights, Raw Story will continue to expose hypocrisy and harm. Unhinged from corporate overlords, we fight to ensure no one is forgotten.

We need your support to keep producing quality journalism and deepen our investigative reporting. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us in the future. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you.



Report typos and corrections to: [email protected]. Send news tips to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Facebook

Greenland row is Donald Trump positioning for an Arctic battle: expert

Published

on

The diplomatic row that has erupted between Washington and Copenhagen over Greenland is just one part of a broader strategic battle being waged over control of the Arctic, according to one expert.

US President Donald Trump has cancelled a trip to Denmark and launched a war of words with his Danish counterpart, Prime Minister Mette Frederiksen, after she rejected his idea of the US buying Greenland as "absurd".

Mikaa Mered, professor of polar geopolitics at Paris' ILERI institute of international relations said Trump's unsolicited advances on the autonomous territory were a way to indicate US interest in the resource-rich Arctic -- and to distract from domestic issues.

Continue Reading

Facebook

‘We won’t give an inch’: India faces defiance in ‘Kashmir’s Gaza’

Published

on

Young men sit beside a pile of rocks and a bonfire, protecting the only entrance to a besieged neighbourhood they call "Kashmir's Gaza" as a mosque loudspeaker broadcasts slogans of liberation.

In an act of defiance against New Delhi's controversial decision to strip the Muslim-majority region of its autonomy, Soura neighbourhood on the outskirts of Kashmir's main city of Srinagar has sealed itself off from security forces.

Since early August, residents have erected ramshackle barricades of tin sheets, wooden logs, oil tanks and concrete pillars, and dug trenches to keep soldiers at bay amid daily protests against India.

Continue Reading
 

Facebook

Second day of Italy crisis talks after prime minister resigns

Published

on

Italy's president will hold a second day of talks aimed at solving the political crisis shaking the country on Thursday after the disintegration of the populist government.

President Sergio Mattarella will meet the main parties, including the anti-establishment Five Star Movement (M5S) and far-right League, after the breakdown of their dysfunctional coalition.

Prime Minister Giuseppe Conte resigned on Tuesday after months of alliance sniping and a bid by League leader and Interior Minister Matteo Salvini to force a snap election, just 14 months since coming to power.

The nationalist, populist government's demonisation of migrants, promoted by Salvini in particular, and attempts to flout EU budget rules had angered many European leaders.

Continue Reading
 
 

Thank you for whitelisting Raw Story!

As a special thank you, from now until August 31st, we're offering you a discounted rate of $5.99/month to subscribe and get ad-free access. We're honored to have you as a reader. Thank you. :) —Elias, Membership Coordinator
LEARN MORE
close-link
close-image